2 WEIGHT LOSS IS A FEATURE OF PROTRACTED METFORMIN THERAPY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME. (1st March 2006)

• Record Type: Journal Article
• Authors: Agloria, M.; Winiarska, M.; Luo, G.; Salehi, M.; Sieve, L.; Aregawi, D.; Wang, P.; Glueck, C. J.
• Is Part Of: Journal of investigative medicine. Volume 54:Number 2(2006)
• Page Start: S373
• Page End: S373
• Publication Date: 2006-03-01
• Subjects: Clinical medicine -- Periodicals; Medicine -- Research -- Periodicals; Medicine; Research -- United States; Clinical medicine; Medicine -- Research; Periodicals; 616.075
• DOI: 10.2310/6650.2005.x0015.80
• Languages: English
• ISSNs: 1081-5589

Abstract

Abstract : In 296 women with polycystic ovary syndrome (PCOS) treated with metformin (MET 2.3 ± 0.4 g/day [Rx]) and diet (1, 500 calories/day if BMI < 25, 2, 000 calories if BMI $ 25 [protein 26% of calories, carb 44%]) for 1, 2, and 3 years, we assessed whether and to what degree weight loss was a feature of 1, 2, and 3 years of MET-diet Rx in women with PCOS. Despite pretreatment (Pre-Rx) group severe obesity, MET-diet was successful in producing group weight reductions of 5.9% at 1 year, 5.8% at 2 years, and 6.3% at 3 years. Weight loss $ 5% was realized by 55% of women at 1 year, 55% at 2 years, and 58% at 3 years, with 15% or more weight loss in 11% of women at 1 year, 14% at 2 years, and 16% at 3 years. At years 1-3 on Rx, weight fell ( p < .05) in BMI groups 25-30 (overweight), 30-40 (obese), and $ 40 (severely obese), and at year 1, in BMI group < 25 (normal). At 1 year follow-up on MET-diet, by stepwise regression, with change in weight as the dependent variable and Pre-Rx weight, age, duration of Rx, and MET dose as the explanatory variables, Pre-Rx weight was a significant positive explanatory variable (p = .017). At 1, 2, and 3 years follow-up on MET-diet, median group HOMA insulin resistance (IR) fell 28% (p < .0001), 42% (p < .0001), and 52% (p < .0001), triglycerides (TG) fell 16% (p = .010), 12% (p = .017), and 19% (p = .011), LDL cholesterol (LDLC) fell 5% (p < .0001), 4% (p = .033), and 8% (p = .014), systolic blood pressure (SBP) fell 4% (p = .0004), 3% (p = .037), and 3% (p = .20), diastolic blood pressure (DBP) fell 6% (p < .0001), 0% (p = .30), and 3% (p = .08). By stepwise regression with explanatory variables age, duration of Rx, MET dose, and weight loss, weight loss was a significant positive explanatory variable for reduction in HOMA IR (year 1 p = .023, year 2 p = .012), was associated with reduction in TG (year 1 p = .005, year 2 p = .007, year 3 p = .043), was associated with reduction in SBP (year 1 p = .0001, year 2 p = .046), and was associated with reduction in DBP (year 1 p = .0001, year 2 p = .016). MET-diet for 1, 2, and 3 years in women with PCOS effectively and safely reduces weight and major atherogenic components of the metabolic syndrome.